RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.

Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.

Add to Collection
2018 Aug Others Fist_Author_Year_PM

Full Author : ['Busch, Catharina', 'Zur, Dinah', 'Fraser-Bell, Samantha', 'Lains, Ines', 'Santos, Ana Rita', 'Lupidi, Marco', 'Cagini, Carlo', 'Gabrielle, Pierre-Henry', 'Couturier, Aude', 'Mane-Tauty, Valerie', 'Giancipoli, Ermete', "Ricci, Giuseppe D'Amico", 'Cebeci, Zafer', 'Rodriguez-Valdes, Patricio J', 'Chaikitmongkol, Voraporn', 'Amphornphruet, Atchara', 'Hindi, Isaac', 'Agrawal, Kushal', 'Chhablani, Jay', 'Loewenstein, Anat', 'Iglicki, Matias', 'Rehak, Matus']
Journal Title : Acta diabetologica
Chapter : Section3
Journal Year : 2018
Cited by : Not Available

AIMS: To compare functional and anatomical outcomes of continued anti-vascular endothelial growth factor (VEGF) therapy versus dexamethasone (DEX) implant in eyes with refractory diabetic macular edema (DME) after three initial anti-VEGF injections in a r.....

Keywords : ["switch continued antivegf therapy versus early switch", "refractory diabetic macular edema", "dexamethasone implant", "stay", "shall", "shall"]